Clinic
Exer Medical Corporation
Exer Medical Corporation was paid $3.77M by Medicaid between Mar 2019 and Dec 2024, across 35 billing codes. Its largest line is 99204, doctor's office visit, new patient (more involved) — 49% of everything it billed.
33Billing provider infoEXER MEDICAL CORPORATION
CALABASAS, CA 91302
CALABASAS, CA 91302
33aNPI1588901532assigned 01/10/2013
33bProvider typeUrgent Care Clinic/Center
28Total paid$3.77M
24GClaims140,531
24DCodes billed35
24AFirst – last monthMar 2019 – Dec 2024
Compared with peers
Next to other Urgent Care Clinic/Center providers in California
Rank by total paid#39 of 284
Median peer was paid$147K
This provider vs. median26×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 184 | $9K | |
| 2020 | 38 | $893.67 | |
| 2023 | 28,972 | $587K | |
| 2024incomplete | 111,337 | $3.17M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 49% | 37,043 | 36,575 | $1.85M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 16% | 18,525 | 17,532 | $605K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 13% | 11,342 | 11,257 | $481K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 12% | 18,545 | 17,956 | $440K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.3% | 4,948 | 4,721 | $125K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.7% | 22,312 | 11,526 | $103K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.0% | 1,482 | 1,446 | $38K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,051 | 2,958 | $36K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 10,603 | 10,495 | $36K |
| 99205 | Prolong outpt/office vis | <1% | 179 | 179 | $14K |
| 87807 | <1% | 1,808 | 1,785 | $8K | |
| 93000 | <1% | 331 | 330 | $6K |
23 more codes
| 71046 | Radiologic examination, chest; 2 views | <1% | 287 | $4K |
| 81003 | <1% | 4,111 | $4K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 441 | $3K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 722 | $3K |
| 81025 | <1% | 1,280 | $3K | |
| 73610 | <1% | 86 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 322 | $1K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 376 | $1K |
| 73630 | <1% | 80 | $1K | |
| 99000 | <1% | 885 | $1K | |
| 94760 | <1% | 860 | $957.74 | |
| 69209 | <1% | 93 | $754.15 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 126 | $698.61 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 76 | $686.51 |
| 81001 | <1% | 305 | $471.12 | |
| 73562 | <1% | 27 | $463.00 | |
| 73130 | <1% | 15 | $297.90 | |
| 86308 | <1% | 68 | $249.24 | |
| 80053 | Comprehensive metabolic panel | <1% | 41 | $210.55 |
| 86580 | <1% | 27 | $79.87 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 15 | $66.94 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 92 | $15.38 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 27 | $1.72 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSPURLOCK, CORY (OWNER)